[gsf_emergency]

>I get value out of

That's the rub. Does it benefit the developers much more than the users, in aggregate?

It's not an easy question to answer even for vaccines..

But I'd wager it's a no, because, e.g. Pfizer(plus or minus BioNTech) probably could not have learnt enough* from their deployment..

*I.e. gain nonfungible knowhow